Non-Hodgkin Lymphoma

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.

Lawrence D. Kaplan, MD, discusses recent updates and next steps in the expanding paradigm of Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma.

The FDA has granted a priority designation to a supplemental new drug application for ibrutinib for use in combination with obinutuzumab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, discusses the use of CAR T-cell therapy in patients with DLBCL and the associated toxicities with each product, as well as other promising therapies in the paradigm.

Combining brentuximab vedotin with frontline chemotherapy led to a statistically significant improvement in progression-free and overall survival in patients with CD30-expressing peripheral T-cell lymphoma, according to topline results from the phase III ECHELON-2 trial.

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

The FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma.

Cure rates in diffuse large B-cell lymphoma remain relatively unchanged, even following therapeutic additions to the armamentarium and an improved understanding of disease biology.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of bridging chemotherapy in patients receiving chimeric antigen receptor (CAR) T-cell therapy.

Philip Bierman, MD, discusses the current landscape of central nervous system involvement in aggressive lymphoma and the research that should be conducted.